NS004 (Nasus Pharma)

NS004 is a preclinical-stage drug candidate being developed by Nasus Pharma for the treatment of metabolic disorders. The drug utilizes Nasus Pharma's proprietary powder-based intranasal (PBI) technology, which is designed to deliver uniform spherical powder particles to the nasal mucosa. This delivery system aims to provide rapid and reliable systemic drug absorption, potentially offering a faster onset of action and higher bioavailability compared to traditional liquid-based nasal sprays. While the specific active ingredient and biological target for NS004 have not been publicly disclosed as of early 2026, the company has indicated that first-in-human Phase 1 clinical trials are expected to commence in the second half of 2026. Notably, earlier company materials from late 2025 associated the NS004 code name with an intranasal formulation of atropine for poisonings, but more recent updates have pivoted the candidate's focus toward metabolic diseases.